Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0345904 (
liver cancer
)
15,188
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Liver cancer
is one of the most common and aggressive tumors, and usually leads to a poor clinical outcome. Increasing evidence has demonstrated the important functions of microRNAs (miRs) in tumor progression. miR-574-3p has been reported as a tumor suppressor and potential therapeutic target in various types of cancer. However, the underlying mechanism of the effects of miR-574-3p in
liver cancer
remains unknown. In the present study, reverse transcription-quantitative PCR was performed to detect miR-574-3p expression in
liver cancer
tissues, and the influence of miR-574-3p on cell growth was evaluated using the Cell Counting Kit-8 assay, and cell migration and flow cytometry analyses. The present study revealed that miR-574-3p expression was downregulated in
liver cancer
tissues and cell lines. miR-574-3p overexpression, achieved by transfecting miR-574-3p mimics into
liver cancer
cells, reduced cell proliferation and migration, and promoted cell apoptosis. Mechanistically,
ADAM metallopeptidase domain 28
(
ADAM28
) was identified as a miR-574-3p target via binding to the 3'-untranslated region of the
ADAM28
mRNA. Gain-of-function of miR-574-3p downregulated the expression levels of
ADAM28
in
liver cancer
cells. Additionally, overexpression of
ADAM28
significantly attenuated the suppressive effect of miR-574-3p on the growth of
liver cancer
cells. The present results provide novel insights into the function of the miR-574-3p/
ADAM28
signaling pathway in
liver cancer
.
...
PMID:MicroRNA-574-3p inhibits the malignant behavior of liver cancer cells by targeting ADAM28. 3278 19
